|

CAR.k.28 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Kappa Chimeric Antigen Receptor and CD28 Endodomain

Pipeline

Phase 1: 1

Top Sponsors

  • UNC Lineberger Comprehensive Cancer Center1

Indications

  • Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue1
  • Nodal Marginal Zone Lymphoma1
  • Splenic Marginal Zone Lymphoma1
  • Indolent Non-Hodgkin Lymphoma1
  • Mantle Cell Lymphoma1

Chapel Hill, North Carolina1 trial

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Lineberger Comprehensive Cancer Center at University of North Carolina

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.